Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics

Novo Nordisk CEO Mike Doustdar highlights the potential of the company's obesity drugs, such as Ozempic and Wegovy, to impact longevity and other healthcare areas beyond weight loss. The drugs' active ingredient, semaglutide, shows possible benefits for organ protection and slowing aging-related processes, even before significant weight loss. Investors are urging the company to diversify as competitors like Eli Lilly expand into broader markets.